EGFR and non-small cell lung carcinoma: However, despite availability of massive, parallel-sequencing technologies enabling efficient, simultaneous detection of driver mutations in lung cancer15, 16, up-front assessment of EGFR mutation status in all patients with advanced NSCLC is not attainable for a number of reasons, including non-evaluable/unavailable samples (in approximately 20% of the samples) and lack of access to affordable testing technologies, particularly in the Asia-Pacific region and other less developed regions of the world17.